公开(公告)号：US20190240199A1

公开(公告)日：2019-08-08

申请号：US16318468

申请日：2017-07-20

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Iris LAVON BEN MOSHE ,  Tamar CANELLO AVRAMOVITCH

IPC: A61K31/4166 ,  A61P35/00 ,  A61K31/517 ,  A61K31/175 ,  G01N33/50 ,  G01N33/574

CPC classification number: A61K31/4166 ,  A61K31/175 ,  A61K31/517 ,  A61K45/06 ,  A61P35/00 ,  G01N33/5011 ,  G01N33/57407 ,  G01N2800/52 ,  A61K2300/00

Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.